Matrixyl

Overview

Matrixyl is the trade name introduced in 2000 by the French company Sederma SAS. Its active ingredient is Palmitoyl Pentapeptide-4 (called Palmitoyl Pentapeptide-3 before the INCI naming standard was corrected in 2006), chemically a palmitic acid (16-carbon fatty acid) chain conjugated to the pentapeptide Lys-Thr-Thr-Lys-Ser (KTTKS), commonly abbreviated Pal-KTTKS. This pentapeptide sequence is a natural degradation fragment of type I procollagen (a matrikine, or matrix-derived signal peptide); palmitoylation was added to improve lipophilicity, skin stability, and transdermal penetration. Ask sales for the Certificate of Analysis matched to the offered or supplied batch. The certificate is authoritative for the tests, specifications, and results recorded for that lot; any additional purity, identity, appearance, or water-content work must be agreed before quotation.

Applications & buyer fit

Cosmetic-peptide buyers fall into two groups: established beauty / med-aesthetic brands extending an existing line, and OEM clients building a private-label catalog from scratch. The first group usually wants active material plus stability data in their existing carrier matrix; the second usually wants a finished formulation under their label. Both need INCI naming verified, regulator-specific safety files (CPNP for EU, FDA OTC monograph for US where relevant), and packaging-compatibility data.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

214047-00-4

Molecular Formula

C39H75N7O10

Molecular Weight

802.07 Da

Sequence

Pal-Lys-Thr-Thr-Lys-Ser

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

10 mg

Packaging

10 vials/box · base pack (multiples of 10)

MOQ

On request

Lead time

10–18 days

Storage

2–8°C, protect from light

Certificate of Analysis

Representative COA previews for Matrixyl; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

Matrixyl

VD260428-MX10132 · 99.64%

Regulatory note

Research-use-only reference material; not for human or veterinary use.

Selected literature

1. Katayama K, Armendariz-Borunda J, Raghow R, Kang AH, Seyer JM. A pentapeptide from type I procollagen promotes extracellular matrix production. J Biol Chem. 1993;268(14):9941-9944.
2. Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):155-160.
3. Choi YL, Park EJ, Kim E, Na DH, Shin YH. Dermal stability and in vitro skin permeation of collagen pentapeptides (KTTKS and palmitoyl-KTTKS). Biomol Ther (Seoul). 2014;22(4):321-327.
4. Park H, An E, Cho Lee AR. Effect of palmitoyl-pentapeptide (Pal-KTTKS) on wound contractile process in relation with connective tissue growth factor and alpha-smooth muscle actin expression. Tissue Eng Regen Med. 2017;14(1):73-80.
5. Aruan RR, Hutabarat H, Widodo AA, Firdiyono MTCC, Wirawanty C, Fransiska L. Double-blind, randomized trial on the effectiveness of acetylhexapeptide-3 cream and palmitoyl pentapeptide-4 cream for crow's feet. J Clin Aesthet Dermatol. 2023;16(2):37-43.
6. Vitali A, Paolicelli P, Bigi B, Trilli J, Di Muzio L, Carriero VC, Casadei MA, Petralito S. Liposome encapsulation of the palmitoyl-KTTKS peptide: structural and functional characterization. Pharmaceutics. 2024;16(2):219.

Frequently asked questions